What's Going On With G1 Therapeutics Stock?
What's Going On With G1 Therapeutics Stock?
G1 Therapeutics, Inc. (NASDAQ:GTHX) shares are trading higher Thursday amid M&A blog speculation of a takeover offer.
由於併購博客猜測收購要約，G1 Therapeutics, Inc.（納斯達克股票代碼：GTHX）股價週四走高。
What To Know:
要知道什麼：
According to a report from Seeking Alpha, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the report, one offer from TerSera is rumored to have a contingent value right which could value the company at between $12 and $14 per share.
根據Seeking Alpha的一份報告，G1 Therapeutics已收到並拒絕了TerSera Therapeutics的多項報價。根據該報告，有傳言稱TerSera的一項報價具有或有價值權，該公司的估值可能在每股12至14美元之間。
G1 Therapeutics shares are climbing on heavy trading volume as investors digest the rumors of a possible takeover offer. According to data from Benzinga Pro, more than 25.4 million shares have already been traded in the session, compared to the stock's 100-day average of 1.136 million shares.
隨着投資者消化有關可能收購要約的傳聞，G1 Therapeutics的股價因大量交易量而攀升。根據Benzinga Pro的數據，該交易日已經交易了超過2540萬股股票，而該股的100天平均交易量爲113.6萬股。
Needham analyst Gil Blum has a Buy rating and $12 price target on G1 Therapeutics, and HC Wainwright & Co. recently maintained its Buy rating and $9 price target on the stock.
Needham分析師吉爾·布魯姆對G1 Therapeutics的評級爲買入，目標股價爲12美元，HC Wainwright & Co. 最近維持了該股的買入評級和9美元的目標股價。
Related News: What's Going On With Affirm Stock After Earnings?
相關新聞： 盈利後Affirm股票怎麼了？
GTHX Stock Prediction 2024:
2024 年 GTHX 股票預測：
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
股票研究可以成爲了解公司基本面的寶貴信息來源。分析師根據公司的基本面和預期的未來收益創建財務模型，以確定股票的目標股價和建議。
Shares of G1 Therapeutics have an average 1-year price target of $10.17, representing an expected upside of 75.65%.
G1 Therapeutics的股票1年平均目標股價爲10.17美元，預計上漲幅度爲75.65％。
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on G1 Therapeutics, while 6 analysts have bullish ratings. The street high price target from Needham is $12, while the street low from Wedbush is $4.
由於假設的差異，分析師可以得出截然不同的目標價格和建議。沒有分析師對G1 Therapeutics提出看跌建議，而6位分析師的評級看漲。尼德姆的街頭高價目標價爲12美元，而Wedbush的街頭最低價爲4美元。
GTHX Price Action: According to Benzinga Pro, G1 Therapeutics shares are up 17.85% at $5.06 at the time of publication Thursday.
GTHX價格走勢：根據Benzinga Pro的數據，截至週四發佈時，G1 Therapeutics的股價上漲了17.85％，至5.06美元。
Image: james-yarema from Unsplash
圖片：來自 Unsplash 的 james-yarema